Jane Street Group, LLC Nymox Pharmaceutical Corp Transaction History

Jane Street Group, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.28 - $0.74 $7,035 - $18,593	25,126 New	25,126 $8,000
Q1 2022 May 17, 2022	SELL	$1.21 - $2.0 $31,046 - $51,316	-25,658 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$0.95 - $2.1 $24,375 - $53,881	25,658 New	25,658 $33,000
Q3 2021 Nov 16, 2021	SELL	$1.3 - $2.23 $54,926 - $94,219	-42,251 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.46 - $2.48 $61,686 - $104,782	42,251 New	42,251 $67,000
Q4 2020 Feb 17, 2021	SELL	$1.84 - $2.83 $79,215 - $121,837	-43,052 Closed	0 $0
Q3 2020 Nov 17, 2020	SELL	$2.3 - $3.66 $92,618 - $147,384	-40,269 Reduced 48.33%	43,052 $106,000
Q2 2020 Aug 17, 2020	BUY	$2.1 - $4.6 $134,941 - $295,586	64,258 Added 337.08%	83,321 $296,000
Q1 2020 May 15, 2020	BUY	$1.69 - $3.88 $32,216 - $73,964	19,063 New	19,063 $45,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.